SCHEMBL517162

SCHEMBL517162

O=S(=O)(Cl)c1c[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.47
ALDH1A1 P00352 3/20 0.46
GPR84 Q9NQS5 2/20 0.46
IMPDH2 P12268 2/20 0.46
GAA P10253 1/20 0.46
CYP2A6 P11509 1/20 0.46
ATM Q13315 2/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
AHR P35869 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PBRM1 Q86U86 1/20 0.43
PRKD3 O94806 1/20 0.42
CCNB2 O95067 1/20 0.42
CCNE2 O96020 1/20 0.42
ABL1 P00519 1/20 0.42
PRKCG P05129 1/20 0.42
PRKCB P05771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27148809 0.83 SLC22A6 (0.50) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL28939777 0.82 SLC22A6 (0.49) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL329511 0.80 SLC22A6 (0.56) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL15415994 0.80 PBRM1 (0.52) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL30727452 0.80 PARP1 (0.50) ALDH1A1KMT2AMEN1CYP3A4TDP1
SCHEMBL32896 0.80 CYP3A4 (0.48) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL3282669 0.80 PARP1 (0.50) ALDH1A1KMT2AMEN1CYP3A4TDP1
SCHEMBL5513343 0.80 SLC22A6 (0.47) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL29557960 0.80 PBRM1 (0.52) SLC22A6ALDH1A1GPR84IMPDH2GAA
SCHEMBL20163593 0.79 CYP19A1 (0.50) SLC22A6ALDH1A1GPR84IMPDH2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137697-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF UNIV DE MONTREAL (CA) 2026-05-21 US disclosed
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 CN disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
EP-4602047-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF The Universite de Montreal (CA) 2025-08-20 EP disclosed
EP-4590666-A1 THIAZOLE DERIVATIVES AS TAU AGGREGATION INHIBITORS WisTa Laboratories Ltd. (SG) 2025-07-30 EP disclosed
CN-120035595-A Thiazolo [5,4-d ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2025-05-23 CN disclosed
CN-119894874-A Thiazole derivatives as TAU aggregation inhibitors 维斯塔实验室有限公司 2025-04-25 CN disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
CN-101005838-A Cannabinoid receptor ligands SCHERING CORP (US) 2007-07-25 CN disclosed
EP-1768667-A1 CANNABINOID RECEPTOR LIGANDS SCHERING CORPORATION (US) 2007-04-04 EP disclosed
US-20060100228-A1 Cannabinoid receptor ligands SCHERING CORPORATION 2006-05-11 US disclosed
WO-2006002133-A1 CANNABINOID RECEPTOR LIGANDS SCHERING CORPORATION (US) 2006-01-05 WO disclosed
US-20050124620-A1 Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's FREDERICKSON MARTYN (GB) 2005-06-09 US disclosed
EP-1495016-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE Astex Technology Limited (GB) 2005-01-12 EP disclosed
WO-2003087087-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE ASTEX TECHNOLOGY LIMITED (GB) 2003-10-23 WO disclosed
US-4836846-A PRE/POST EMERGENCE; WEEDS, GRASSES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-06-06 US disclosed
US-4764610-A Herbicidal indole sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-08-16 US disclosed
EP-0070698-B1 HERBICIDAL INDOLE SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100228-A1 Cannabinoid receptor ligands CNR1, CNR2, TRPV1 SLC22A6 2073/4885ALDH1A1 2088/4885GPR84 35/4885
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS SLC22A6 2809/4885ALDH1A1 1636/4885GPR84 4009/4885
US-20050124620-A1 Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's MAPK1, IDO1, INMT SLC22A6 2712/4885ALDH1A1 1044/4885GPR84 2788/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS SLC22A6 2809/4885ALDH1A1 1636/4885GPR84 4009/4885
US-20260137697-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NRAS, KRAS, BRAF SLC22A6 3148/4885ALDH1A1 2369/4885GPR84 4343/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS SLC22A6 2809/4885ALDH1A1 1636/4885GPR84 4009/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD SLC22A6 2755/4885ALDH1A1 1619/4885GPR84 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.